<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02843867</url>
  </required_header>
  <id_info>
    <org_study_id>R/2011/44</org_study_id>
    <nct_id>NCT02843867</nct_id>
  </id_info>
  <brief_title>Orientation of the Lymphocyte Response to the Occurrence of Atherosclerotic Complications After Kidney Transplantation</brief_title>
  <acronym>ORLY-Est</acronym>
  <official_title>Influence de l'ORientation de la réponse LYmphocytaire Sur la Survenue de Complications athéromateuses après Transplantation rénale (étude ORLY-EST 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Franche-Comté</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Etablissement Français du Sang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of atherosclerotic complications is increased after kidney transplantation.
      Traditional risk factors do not fully explain this increased risk. Atherosclerosis is an
      inflammatory disease in which all players in the immune response are involved. The impact of
      these immune responses is not well known in immunocompromised patients, particularly among
      organ transplant. Nevertheless, the work of our group suggest that innate and acquired
      responses through different mechanisms influencing the evolution of atheromatous disease
      after transplantation.

      The investigators therefore propose to study the impact of the expansion of regulatory T
      cells on the risk of atherosclerotic complications after transplantation.

      Since November 2008, the investigators began a multicenter, prospective study whose purpose
      is to study in detail the immunological mechanisms of atherosclerosis after transplantation
      via immunomonitoring cohort of renal transplant patients in the Grand East Interregion. It
      was planned to include 500 patients and to date a little more than half have been included.
      After completion of the blood test, the tubes are routed over the Biomonitoring Platform
      (CIC-BT 506 Besançon) and the samples are stored in CRB Dijon.

      The atherosclerotic events are recorded prospectively. The investigators hope to implement as
      part of ORLY IS, a second study to determine the impact of an expansion of regulatory T cells
      on the risk of atherosclerotic events.

      Our hypothesis is that a cell rate regulatory T below the median results in an increase of 5%
      of atherosclerotic complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of regulatory T cells related to atherosclerotic complications events.</measure>
    <time_frame>5 or 10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atherosclerotic complications events</measure>
    <time_frame>5 or 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic determinants (TNF-alpha, IL-6,...) related to cardiovascular events</measure>
    <time_frame>5 or 10 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Disorder Related to Renal Transplantation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>36 ml of blood sample at D0 and 1 year after transplantation</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum Peripheral Blood Mononuclear Cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population corresponds to 1000 patients receiving a renal transplant in Hospital
        of Besançon, Dijon, Nancy, Reims, Clermont-Ferrand, Strasbourg et Kremlin-Bicêtre.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged over 18 years

          2. Patients receiving a renal transplant

          3. Patients able to understand the benefits and risks of testing

          4. Patients gave written informed consent.

        Exclusion Criteria:

          1. Inability to understand the advantages and disadvantages of the study; psychiatric
             disorders judged by the investigator to be incompatible with the inclusion in the
             study.

          2. Immunosuppressive therapy immediately prior to transplantation

          3. Cancer (except skin cancer) or malignant blood disease being treated; active
             infection; decompensated cirrhosis [patients had cancer and considered as cured or in
             remission, patients with virus infection of hepatitis B or hepatitis C and having no
             cirrhosis may be included].

        This study is strictly non-interventional, participation in another study is not a
        cons-indication to the inclusion in this study and no exclusion period is required for
        inclusion in another study after inclusion in this study (Art L. 1121-12 (loi n°2004-806 du
        9 Août 2004).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Ducloux, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Didier Ducloux, Pr.</last_name>
    <email>dducloux@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie Gaiffe, Dr.</last_name>
    <email>egaiffe@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Ducloux, Pr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand, 58 rue Montalembert, 63003 Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Detex, Pr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dijon, Hôpital du Bocage, 2 Bd du Maréchal de Lattre de Tassigny, 21079 Dijon cedex</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Mousson, Pr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital du Kremlin Bicêtre 78, rue du Général Leclerc, 94275 Le Kremlin-Bicêtre Cedex</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Durrbach, Pr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brabois, et Vandoeuvre les Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Reims, 45 rue Cognacq-Jay 51092 Reims Cedex</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil- 1, place de l'hôpital BP426 ; 67091 Strasbourg Cedex</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>July 21, 2016</last_update_submitted>
  <last_update_submitted_qc>July 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transplantation</keyword>
  <keyword>Immunology</keyword>
  <keyword>Atherosclerosis</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Identified individual participant data for all outcome measures will be made available within 6 monts of study completion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

